Psyence receives MHRA approval for Phase 2 trial
Psyence Group (“Psyence”) has announced formal approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) to commence their highly anticipated Phase 2 trial.
Psyence Group (“Psyence”) has announced formal approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) to commence their highly anticipated Phase 2 trial.
Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.
Hannam & Partners issued an independent research report on Psyence identifying it as a first mover into the palliative care market supported by natural psilocybin production.
We are pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the “Private Placement”) raising gross process of $1.273 million.
Psyence Group Corporate Update
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements [...]
TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).
Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.